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Abstract
The DNA-chips are almost a decade old and by now have brought an explosion in genetics. With
their ability to investigate the biological systems in their complexity microarray experiments resulted
in enormous amount of complex data. It will be a challenge for biologists, statisticians and for
information technology engineers to develop capable methods for coping with the analysis, validation
and interpretation. This revolutionary new field of biology demands absolutely new algorithms,
analytical methods and new ways of thinking combined with effective team-work. No doubt that
DNA-chips will shortly be very useful and essential technology in the diagnostic and therapeutic
processes. In this review we shortly introduce the most important types of DNA-chips and describe
their capability and limitations to be clear how to position them in the future scientific ways of
thinking.
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1. Introduction
DNA-chips are a revolutionary new method in genetics and brought breakthrough
in the diagnostic and therapeutic regimen. It makes possible to perform thousands
of experiments parallel which gave hope for gaining some insight into the enor-
mous complexity of the living biological systems and processes [1]. Our life is
made of thousands of processes working simultaneously and before DNA-chips the
investigators were able to follow only a limited number of various factors. Usually
a distinct change of a gene does not make manifesting effect, but joining other
concomitant changes it could lead to significant illnesses [2]. More diseases, orig-
inating from quite different ways can look very alike, and therefore the adequate
therapy can be very different. Colorectal cancers might cause the same symptoms,
but studies revealed more different ways and genes of tumor development in bowels
[3].
The growing palette of molecular investigating methods can bring more in-
sight and better understanding into the development of special conditions and in
turn discovering novel potential therapeutic targets. Investigating of signal trans-
duction processes recently led to a targeted blockage of a specific kinase, which is
proved to be very successful in the treatment of chronic myelogenous leukemia and
gastrointestinal stromal tumors, and resulted in much better prognosis [4].
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2. DNA-Chips
DNA-chips is a phrase appertaining a little device with lots of individual areas
covered with millions of uniform DNA-sequences. It works upon the characteristic
and inevitable feature of hybridization of nucleic acids. During hybridization two
complementary sequences (they match to each other, like the key fits the lock) will
find and join each other. Hybridization is a key and very accurate process in biology
in duplicating the DNA and in functioning and controlling the genes, and that is
why this approach is very suitable for a broad kind of experiments.
The inventor of DNA-chips is the Affymetrix corporation in California [5].
They use photolithography (like in case of integrated circuits, hence comes the
name) to produce their patent pended Genechips. For today there are very many
kinds and ways of producing DNA-chips which led to many names: DNA-arrays,
DNA-matrices, microarrays, macroarrays and also to a confusing variety of devices
and literature.
Fig. 1. Affymetrix uses photolithography for manufacturing high density oligonucleotide
GeneChips, of which resolution is in nanometer range (www.affymetrix.com)
The basic idea of the DNA-chips: make a very small device of individual
affinity sensors and cover it with different sequences. If it is small enough it is
capable of putting even hundreds thousands of sensors on a little surface and so it
wouldbepossible to performahugenumber of various experiments at the same time.
The DNA-chip contains the investigatory sequences (probes) bound to its surface
at well-known and circumscribed places. The unknown sample which should be
investigated can be hybridized onto it and relevant data should be read indirectly.
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The probes on the DNA-chip may be of DNA, RNA, specially modified se-
quences or even protein and antibodies and depending on the purpose of the DNA-
chip. In vast majority the chips are made of DNA-sequences. The quality and
quantity of hybridization depends on environmental conditions and factors (pH,
temperature, pK, ion-strength etc.) but the most important thing is the complemen-
tarity of the two sequences. The stable double helix of DNA is made up of two
antiparallel strands of desoxyribonucleic acids and this structure makes them very
appropriate for their function of containing all information of life in a secure and
easy readable way. Hybridization happens according to thermodynamic rules and
has optimal length and base-content. Short sequences are bound to each other less
strongly than longer ones, while too long sequences are too robust and can form
the stable double helix inside their own single stranded chain. Base-sequence is
crucial in determining the number of possible bounds and the strength and optimal
temperature of hybridization. All these issues should be cared very cautiously in
assembling a DNA-chip.
The investigated sample should be prepared, amplified and labelled in away to
be able to hybridize and afterwards detected on the chip. Among many possibilities
fluorescent labelling is themostwide-spread: dyes boundedcovalently to the sample
can be excited and detected with laser-scanners. In the enzyme-linked method the
production of a special substrate (chemiluminescent) is used without laser. In the
knowledge of the sharing out of the chip, after hybridization and detection we
can determine the quality and quantity of the hybridized investigated sequences
indirectly.
According to the surface density of aDNA-chipweused to talk aboutmacroar-
rays and microarrays. Macroarrays are less surface density chips for investigating
around several dozens or hundreds of sequences and offer a simpler structure and
instrumentation and therefore an easier way to perform investigations. The generat-
ing fewer data is usually still enough for investigating a certain condition, disease or
question so macroarrays might therefore be more widely spread. The high density
DNA-chips, the microarrays might contain probes for determining the expression
profile of all human genes (round 30000) simultaneously. These microarrays are
really sophisticated devices and need high accuracy, expensive and very reliable
instrumentation and a specialized team of experts to cope with the enormous raw
data generated. Therefore the high-density microarrays can be exploited only in
limited number of laboratories.
DNA-chips can be also sorted according to the manufacturing type of se-
quences. Affymetrix and a couple of another manufacturer build up the nucleic
acid sequences right on the surface of the chips via the so-called in situ synthesis.
This technology yields high accuracy, quality control and enormous surface density
but is limited in size and sequence length due to the high instrumentation needs.
Cheaper, simpler and more widely used method is the postsynthetic immobilization
of ready nucleic acid sequences. Many research laboratories have built own plotter
machines to put their in-house-made probe sequences on the surface of a glass-slide
and then use UV-crosslinking technique to immobilize them on the surface of the
chips. This method is simpler to perform and more variable and adjustable to the
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Fig. 2. Comparison of a macroarray (left, 112 quadraspots) with a microarray (right, about
3600 spots). (www.superarray.com, www.affymetrix.com ).
special needs of the laboratory and has its benefits for being so widely used, but
has its crude limitations in quality control and reproducibility. A lots of special,
home-made and company-manufactured chips are in use and the most striking ex-
perience with them is the lack of reproducibility and coincidence of results coming
from the various laboratories. This is the main drawback of further utilization of
DNA-chips.
DNA-chips are able to perform thousands of processes parallel and automated,
but can not think instead of us - just like computers. Hybridization is just part of
investigation and for best utilization it is inevitable to ask good questions and think
over the investigations, layout of the chip carefully to bring real new results into
science. Listing the findings is useless: the collected raw data should be analysed
and interpreted in useful and cautious ways to make sense of the sequence [6].
2.1. Diagnostic DNA-chips
A certain condition which can be caused by several mutations or alterations in the
DNA sequence can be pointed out with a series of experiments, although this can
be cost, time and labour-consuming. If we have already learnt all the numerous
possible causative changes for a condition and want to find quickly the actual one
then it is high time for using a diagnostic DNA-chips. We use all the possible
investigating probes and perform all experiments simultaneously in several hours
instead of weeks. The otherwise long and labour-intensive work can be cut out and
better and adequate therapy might be started much sooner, which in turn can lead to
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better efficacy of treatments with less costs and side-effects. In these cases we are
looking for quality information, for a presence or absence of a special alteration. It
is most suitable, when there are a lot of possible causes, but we can combine tests,
too. First applications are with HIV, cystic fibrosis, Ct-P450 enzymes, BRCA-
mutations etc.[7] Diagnostic DNA-chips can be used also for research tools, like
metilation detection.
Lots of infectious diseases can look very similar, and better treatment can be
achieved by diagnostic applications of DNA-chips[8]. Furthermore, if we would
like to be very cautious, wemight test the pathogen and the host body of the infected
people to find out which medicamentation would be most useful and effective with
the least side-effects[9]. Huge expenses in health care go for curing harmful side-
effects, which could be avoided with better diagnostic tools and individualized
therapy. This means that curing a patient would not only mean the following
of an accepted and quite effective, but still empiric algorithm, but making special
investigations to find the best possible and effective therapy from the lots of possible
ones. DNA-chips are very advantageous in speeding up this development [10].
2.2. Gene-expression Monitoring
In biological systems DNA is the source of all information, which is transcribed to
messengerRNA to travel out from the nucleus and being translated intoworking pro-
teins. Proteins are the very engines of cells and they are catalyzing and controlling
all biological processes, so cell functions can be traced by the amounts of present
proteins and indirectly mRNA. DNA-chips are highly perfect for determining si-
multaneously thousands of various mRNA levels in certain space and time[11]. The
sensitive gene expression monitoring needs more caution and strict environmental
conditions, but brought a very useful and promising way for obtaining insight in
disease and cancer development. The inestimable benefit of the application of
DNA-chips is the view of the gene-network in its complexity and with the capacity
of analysing thousands of regulating factors and proteins simultaneously [12].
Rarely a single mutation can cause severe illnesses, but more often many
factors with a slight imbalance lead to the development of a disease. DNA-chips
make it possible to investigate all the 30000 genes simultaneously of the human
body. This enormous amount of data is really admirable and results in quite dif-
ferent possibilities of investigations. Analysing the network of the working and
controlling genes or proteins of the systems can reveal key-processes and factors.
This so-called ‘gene-fishing’ in the whole genome is made by statistical and math-
ematical methods and cooperation between the different workgroups of biologist,
statisticians, information technologists. Determining key-processes and proteins
could result in gaining better understanding of biological systems and in finding
new therapeutic targets [13].
For gene expression monitoring we take the sample of the patient immedi-
ately after removal from the living body. After isolating RN
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Fig. 3. The process of gene expression monitoring [13].
and amplification method should be used to gain detectable amounts of nucleic acid
sequences for hybridization. Gene expression monitoring can be made by cDNA
(RNA isolated from cells are reverse transcribed to cDNA) or by directly synthe-
sized oligonucleotides. Both techniques are widely spread but now it seems that
oligonucleotides offer a better way because of the less uncertainty in the hybridiza-
tion process.
The quality of the very sensitive and rapidly degraded mRNA is very crucious
because of the need for quantitative data. Furthermore, a biological sample contains
several kinds of cells, which could be not all involved in disease development. For
example cancerous sample contains comparable amount of stromal and other cells,
which have quite other functions and in turn gene expression levels, therefore data
could be not relevant for only the cancer cells. In some extent it’s not a problem,
because in cancer growth other cell types are also involved, and cancer can not
grow without the parallel growing of feeding stroma: the growth of stroma is also a
possible issue in cancer therapy. With bulk sample we will have enough mRNA to
work with, but could be afraid of gaining not true and relevant data about involved
genes because of the contaminating cells. Most convincing works and results have
been conducted on pure samples containing only one type of cells, but it is more
or less accepted, that an involved genes altered expression could be investigated
also with bulk samples. The interaction of cancer cells and their environment is
also essential in the spreading of cancer and this could also be investigated only
with bulk samples. If we cut out only the investigated tumor cells of a bulk sample
with laser capture microdissection in a long and tiring process with an expensive
machine we will get so few cells and mRNA that should be amplified very strongly
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and this in turn can cause false data because of the nonlinearity of the amplification
methods. Both methods have their backs and fors and the literature is not sure about
the proper way of investigating.
An emerging way of investigating bulk samples without microdissection is
the post-processing of the scanned data via mathematical and statistical methods.
With the power of computers and access to various databases it is possible to effec-
tively search for new target genes even from bulk tissue samples [14]. If we build
up a statistical database of the various gene expression data of pure cells and tissues
in advance, we will be able to deal with the gene expression data coming from bulk
tissues. This could be simply made by substracting the gene activities coming from
the contaminating cells from the bulk results, but with Boolean operators it is pos-
sible to search databases for expression patterns of interest in a more sophisticated
method. This method is also applicable in tissues, where the pathological pathway,
the cause and consequence are not really clear: for example various inflammations,
chronic diseases. The generation of the pure gene expression databases of various
tissues (muscle-, soft tissue , mucosa-associated genes) could be used in separating
of samples into their constituents and analysing simultaneously and also separately
each cell type and the various pathological pathways (and their network) to reveal
interactions of the various cells, tissues and their roles in disease development and
propagation [15]. Another successful approach of searching for new genes in cancer
and disease development is the use of neural networks [16].
3. Data Interpretation and Validation
The real brain-work begins just after detecting the hybridized sequences on the chip
to find out the meaning of the results. All experiments should be made at least in
duplications and should be reproducible. DNA-chip technology is relatively new
and can not be used as only diagnostic tool yet, but needs strict validation process,
in which the experiment is repeated with a different and independent investigation
method and concludes to the same results.
In case of diagnostic DNA-chips it is quite straightforward to perform a PCR
or some blotting with the same sample but with gene expression studies the situation
is more complicated and validation is a real problem. Gene expression monitor-
ing DNA-chips now are mostly used as research tools for gaining new insights
and ‘fishing’ for new key-factors. This means that these chips are working in a
relatively unexplored and uncertain area and therefore relatively few background
and reliable information is available. Furthermore, gene expression is valid for a
cell/tissue at a moment and at a certain place: it is just a snapshot from the cell.
Because the many uncertainty only the significantly altered genes are to deal with
and normalization, standardization should be made very carefully. Normalization
happens usually against equally expressed, ‘housekeeping genes’. Significantly
altered expressions should be validated with other investigation methods (blotting,
real-time quantitative PCR) and here we are facing a doubtful issue: the data com-
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ing from the various microarray experiment are not always prone to be validated by
other methods. Often the data are controversary and only a small percent of data
coincides with other technics or with the results of other laboratories investigat-
ing the same disease [17]. The biggest problem with microarray studies remains
reproducibility and validability [18].
Microarray technique is a rather expensive one and therefore many laborato-
ries made up their own custom-made spotted cDNA-microarrays[19], what resulted
in a lot of investigatory methods and lots of kinds of used arrays, without the abil-
ity to compare results. A cDNA sequence is about 100-1000 nucleic acid long
and more instable and therefore huge crowd and conformity changes can occur
disturbing the hybridization process[20]. A lot of interesting and important gene-
functions could be revealed with cDNA-s, but for the more reliable and comparable
data it would be advantageous to use shorter sequences, the 25-70 nucleic acids
long oligonucleotides.
Fig. 4. 3D conformation and molecular interactions influence hybridization with cDNA
[20].
Affymetrix uses sets of short oligonucleotides for testing a single gene and
usually two dozens of 25-mer oligonucleotides are pointing on different sequences
of the same gene. Data analysis is restricted to the genes which concluded to the
same intensity at all of the investigating sequences, which is a very effective way
of quality assurance. Furthermore Affymetrix continuously builds up a database
from all the experiments performed with GeneChips making it possible for every
user to compare data and to instantly improve data analysis methods [21]. Quality
assurance issues are managed somehow by the other DNA-chip manufacturers as
well, but they are rather concentrating on the clear and reliable manufacturing
methods.
The other possibility to build up reliable databases and compare various exper-
iments leads through mathematical and statistical methods and these postprocessing
algorithms could improve a lot in the reliability ofmicroarray. Gathering all the data
and systematically grouping them is a huge work but inevitable in progressing in
scientific means [22]. The generated huge amount of data coming from microarray
studies would also need newmethods and algorithms for viewing and systematizing
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them and to cope with the meanings of parallel gained data and ways of interpreting
them [23]. There are several companies dealing with these issues and many people
working in statistical and computation/information technology field could find new
challenges in this data-mining and in silico techniques.
4. Clinical Use
The first diagnostic DNA-chip was made in 1996 to HIV-infections to find the
most effective therapy in less possible time [24]. For today the list is very long:
www.affymtrix.com, www.superarray.com. In these cases DNA-chips accelerates
the otherwise long diagnostic process, which is advantageous for sure but the cost
for a microarray remained rather high and so the spreading of the technology is still
a bit slow, and will speed up when manufacturing costs become less, especially in
the fields of infectious diseases, predicting adverse events and in forensic science
where rapidity is an important issue and cost is more affordable [25].
Another possibility is the use of macroarrays, which bear less sequences on
their surface resulting less data but they are much cheaper and easier to use. With
their capacity of hundreds of investigating probes tailored and focused on a special
condition or disease they are highly capable of using for clinical and diagnostical
purposes, since differential diagnostic problems usually concern several possibili-
ties and high density microarrays would mean to fire at a sparrow with a huge gun
[26].
No question about that the literature and the investigators are very enthusias-
tic about gene expression monitoring microarrays. The huge capacity, parallelism
and automation undoubtly brought a revolution into the investigation methods and
understanding of cancer and various diseases. Although reproducibility and val-
idation remains still a problem, clustering methods with gene expression studies
already resulted in huge leaps forward. Clustering methods can group the diseases
upon their gene expression data into various groups with different prognosis. There
are also gene expression monitoring macroarrays existing, which are manufactured
according to strict rules and therefore can mean an alternative and better standardiz-
able method of studying several targeted levels of genes instead of the house made
spotted arrays.
One of the very first clinical application of gene expression microarrays was
the differentiation between acut lymphocytic and myelogenous leukemia using a
nearest –neighbour clustering method. The chip was not only able to distinguish
between the two kinds of leukemia neccesitating quite different therapy but even
the prognosis of the diseases could be estimated. This has huge clinical relevance,
because before microarray studies the so called borderline leukemia were not to be
grouped well phenotipically, and therefore adequate therapy could not have been
promising [27].
This first success was rapidly followed by other studies and effective clus-
tering methods upon the gathered data in the case of various cancers: breast[28],
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prostate[29], soft tissue sarcomas[30], colorectal carcinomas[31], lymphomas[32].
These investigations were successful and brought clinical use and relevance of gene
expression data. The data were not only good for clustering the various malignant
diseases into separate groups but these clusters had also differences in patient sur-
vival, disease state, prognosis and so gene expression information really revealed
new insights in cancer research. Newgenes came to spotlight in cancer development
and potential new targets for therapy could be found. This is a real breakthrough
in microarray studies which of course mean a lot of further work and analysis to
be performed but these data could speed up cancer therapy development. Diseases
which could not have been effectively cured before are now more capable to find
the best effective and personalized treatment resulting in better prognosis.
5. Conclusion
The DNA-chips were introduced just about a decade ago and since then a lot of
application was manufactured with them. No doubt they brought a detonation-
like change and improvement in scientific thinking and led to the development of
genomics, proteomics and a lot of other ‘mics’, because of their high-parallelism
and capability to look into the biological processes in their complexity. Lots of
various application methods and technology has been invented but the technology
is a rather expensive one even today and therefore it needs more improvement,
especially in the field of cost effectiveness.
There are several fields of direct usage of microarrays but the validity and re-
producibility is still an issue. Data-mining is also a good field of improvement and
newer algorithms, analytical methods are welcome to be able to cope with all the
generated data and to find clinically relevant meanings and connections. Statistical
methods, clustering methods, generating databases and working with neural net-
works can offer new ways of thinking about biological processes. For today we just
can not cope with all the data generated by microarray studies. For these reasons
DNA-chips remain rather a researchers’ tool than a pure diagnostic technology for
several years more. The modern medical thinking is based on evidences now and
therefore it is essential to perform prospective clinical studies for the fortification
an determination of the position of DNA-chips in diagnostic processes.
The most benefit will come from the gene expression microarray studies.
The new findings are very promising in determining new ways of thinking about
various illnesses, especially in the case ofmalignant diseases. Recent investigations
have already brought new molecular classification, grading and staging methods
for numerous cancer types. However direct usage of gene-expression DNA-chips
will be not right beside the patient’s bed, but instead of performing gross studies
and developing screening tests which will bring new aspects, investigations and
methods in to therapy and treatment. Upon microarray data simpler and easy to
perform screening methods and investigation could be carried out for determining
the more proper diagnoses and in turn to find the most effective therapy in less time.
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